D'Amelio R, Matricardi P M, Di Addario A, Le Moli S, Paganelli E, Nisini R, Sirianni M C, Fattorossi A, Cherchi M, Gaetano C
Divisione Aerea Studi Ricerche e Sperimentazione, Gruppo di Igiene ed Immunologia, Aeroporto Pratica di Mare, Roma.
Boll Ist Sieroter Milan. 1989;68(1):57-61.
Two groups of 18 healthy adults, chosen from a risk population, were vaccinated against hepatitis B virus with French (Hevac B, Pasteur) or American (HB-VAX, MSD) vaccine; immunological and biochemical parameters (HBsAb titers, Ig, IgM-rheumatoid factor (IgM-RF) levels, autologous mixed lymphocyte reaction (AMLR), T4/T8 ratio, lymphocyte migration inhibition test (LMIT) with specific antigen and transaminase levels) were compared at preselected time intervals. The vaccines were found to be clinically safe, as documented by the absence of demonstrable side effects and changes in serum transaminase levels. The positivity of the LMIT test demonstrated an early immunization on day 45 in all subjects tested, along with a marked reduction in AMLR, independent of the vaccine used. A slightly higher, though not statistically significant, percentage of seroconversion was observed for the Pasteur vaccine. This same preparation induced a significant increase in the main Ig classes and in Ig;-RF levels on day 45. This data indicates that aspecific modification of the immune system occur to a greater extent with Hevac B, presumably for its lower degree of purification. Thus, despite the slightly lower efficacy, the HB-VAX might be the preparation of choice in subjects with immunological disturbances.
从有风险的人群中选取两组各18名健康成年人，分别用法国疫苗（Hevac B，巴斯德公司生产）和美国疫苗（HB-VAX，默克公司生产）接种乙肝病毒疫苗；在预先选定的时间间隔比较免疫学和生化参数（乙肝表面抗体滴度、免疫球蛋白、IgM类风湿因子（IgM-RF）水平、自体混合淋巴细胞反应（AMLR）、T4/T8比值、特异性抗原淋巴细胞迁移抑制试验（LMIT）和转氨酶水平）。疫苗在临床上被证明是安全的，表现为无明显副作用且血清转氨酶水平无变化。LMIT试验阳性表明所有受试对象在第45天出现早期免疫，同时AMLR显著降低，这与所使用的疫苗无关。观察到巴斯德疫苗的血清转化率略高，但无统计学意义。同一制剂在第45天使主要免疫球蛋白类别和IgM-RF水平显著升高。这些数据表明，Hevac B对免疫系统的非特异性修饰作用更大，可能是因为其纯化程度较低。因此，尽管疗效略低，但HB-VAX可能是免疫功能紊乱患者的首选制剂。
